LoginSignup
Simulations Plus logo

Simulations Plus

Stock
Stock
Ticker: SLP
SLP

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 

$0.221

CHART BY

Frequently asked questions

The market capitalization of Simulations Plus is $372.54M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Simulations Plus is 46.02. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Simulations Plus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.40. EPS indicates the company's profitability on a per-share basis.
Currently, 4 analysts cover Simulations Plus's stock, with a consensus target price of $17.25. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Simulations Plus reported a revenue of $82.06M.
Simulations Plus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $17.80M. EBITDA measures the company's overall financial performance.
Simulations Plus has a free cash flow of $24.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Simulations Plus employs approximately 213 people. It operates in the Health Care sector, specifically within the Packaged Software industry.
The free float of Simulations Plus is 16.75M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$372.54M
EPS (TTM) 
$0.40
Free Float 
16.75M
P/E ratio (TTM) 
46.02
Revenue (TTM) 
$82.06M
EBITDA (TTM) 
$17.80M
Free Cashflow (TTM) 
$24.54M

Pricing

52W span
$11.11$21.01

Analyst Ratings

The price target is $17.25 and the stock is covered by 4 analysts.

Buy

0

Hold

4

Sell

0

Information

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Durham, NC.

Employees
213
Industries
Packaged Software
Sector
Health Care

Identifier

Primary Ticker
SLP
Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin